Skip to content

Comparative study on the effects of vitamin D screening and intervention on liver fibrosis in patients with chronic liver disease

Comparative study on the effects of vitamin D screening and intervention on liver fibrosis in patients with chronic liver disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124218
Enrollment
Unknown
Registered
2026-05-08
Start date
2026-05-11
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease

Interventions

Research Group:On the basis of routine liver protection therapy, vitamin D screening was carried out, serum 25 (OH) 3 ? level was detected, and targeted vitamin D supplementation therapy was given acc
control group:Routine liver protection treatment was given, including liver protection drugs (such as polyene phosphatidylcholine, silibinin, etc.), etiological treatment (such as antiviral treatment,

Sponsors

Shifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old, regardless of gender 2. The diagnosis of chronic liver disease (including chronic hepatitis B, chronic hepatitis C, alcoholic fatty liver, liver cirrhosis compensatory period, etc.) was confirmed by clinical symptoms, signs, liver function examination, imaging examination (ultrasound, CT, etc.) and etiological examination 3. Voluntarily participate in the study and sign the informed consent form 4. Able to cooperate to complete the whole follow-up and various examinations.

Exclusion criteria

Exclusion criteria: 1. Severe liver failure, liver cancer, hepatic encephalopathy and other complications were observed 2 Complicated with severe heart, kidney, lung, endocrine and other system diseases 3 Recently (within 3 months) taking vitamin D supplements, glucocorticoids, immunosuppressants and other drugs that may affect the results of the study 4 Pregnant or lactating women 5 Allergic to vitamin D supplements 6 Mental illness, cognitive impairment and other patients who cannot cooperate with the study.

Design outcomes

Primary

MeasureTime frame
Serum 25 (OH) D3 level;Alanine Aminotransferase (ALT);Aspartate Aminotransferase (AST);Apri score;Liver stiffness value (LSM);

Secondary

MeasureTime frame
Adverse reactions, including gastrointestinal discomfort, dizziness, fatigue, rash, etc;

Countries

China

Contacts

Public ContactXianrong Yin

Shifang People's Hospital

986705715@qq.com+86 159 8290 0793

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026